Allergen-specific Immunoglobulin E and Immunoglobulin G4 (sIgE and sIgG4)

Allergen-specific Immunoglobulin E (sIgE) and Immunoglobulin G4 (sIgG4) are key components of the adaptive immune system that mediate and modulate allergic responses [Gould et al., 2003, Nature Reviews Immunology]. sIgE is the primary driver of Type I hypersensitivity; it binds to high-affinity FcεRI receptors on mast cells and basophils, where allergen-induced cross-linking triggers the release of inflammatory mediators like histamine [Gould & Sutton, 2008, Nature]. In contrast, sIgG4 acts as a blocking antibody by competing with IgE for allergen binding without triggering degranulation, thereby inhibiting the allergic cascade [Shamji et al., 2011, JACI]. The balance between these two antibodies is a critical determinant of allergic sensitization versus clinical tolerance [Durham & Shamji, 2023, NEJM]. Therapeutic strategies include monoclonal antibodies like Omalizumab, which neutralizes free IgE to prevent its interaction with receptors [NCBI, 2023, PubChem], and allergen immunotherapy (AIT), which aims to shift the immune profile by inducing sIgG4 production [Shamji & Durham, 2017, JACI]. Monitoring the levels and ratios of sIgE and sIgG4 serves as a vital tool for diagnosing allergies and assessing the efficacy of desensitization treatments.

Other names

Allergen-specific IgEAllergen-specific IgG4sIgEsIgG4Blocking antibodiesReaginic antibodies

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with FcεRI on mast cells and basophils [NCBI, 2023, PubChem]. Allergen immunotherapy (AIT) induces the production of allergen-specific IgG4, which acts as a blocking antibody to intercept allergens before they can cross-link IgE on effector cells [Shamji et al., 2011, JACI].